Resource Summary Report

Generated by NIF on Apr 18, 2025

SOCS

RRID:SCR_013223

Type: Tool

Proper Citation

SOCS (RRID:SCR_013223)

Resource Information

URL: http://sourceforge.net/projects/socs/

Proper Citation: SOCS (RRID:SCR_013223)

Description: Performs ungapped alignment of SOLiD (color space) sequencing reads

against reference sequences.

Abbreviations: SOCS

Resource Type: software resource

Funding:

Resource Name: SOCS

Resource ID: SCR_013223

Alternate IDs: OMICS_00590

Record Creation Time: 20220129T080314+0000

Record Last Update: 20250410T070344+0000

Ratings and Alerts

No rating or validation information has been found for SOCS.

No alerts have been found for SOCS.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 74 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Shi W, et al. (2025) Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis. BMC pharmacology & toxicology, 26(1), 11.

Yilmaz Koc O, et al. (2025) The Relationship of Th1/Th2 Cytokine Polarization at Parturition in Cows and SOCS3 Level With Some Postpartum Diseases. Veterinary medicine and science, 11(1), e70137.

Shizu K, et al. (2024) Quantitative prediction of rate constants and its application to organic emitters. Nature communications, 15(1), 4723.

Yue QX, et al. (2024) Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study. Journal of medical Internet research, 26, e48572.

Chen J, et al. (2024) Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. Frontiers in pharmacology, 15, 1371346.

Choi JY, et al. (2024) Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System. Pharmaceuticals (Basel, Switzerland), 17(3).

Xu Y, et al. (2024) Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS. Frontiers in pharmacology, 15, 1438292.

Bromberg DJ, et al. (2024) Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal of the International AIDS Society, 27(2), e26202.

Guo H, et al. (2024) Global distribution of surface soil organic carbon in urban greenspaces. Nature communications, 15(1), 806.

Minucci SB, et al. (2024) Agent-based vs. equation-based multi-scale modeling for macrophage polarization. PloS one, 19(1), e0270779.

Li Y, et al. (2024) Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis. JMIR public health and surveillance, 10, e51007.

Wei S, et al. (2024) Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024. Frontiers in pharmacology, 15, 1491921.

Ruan Z, et al. (2024) High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database. Frontiers in pharmacology, 15, 1460407.

Jain A, et al. (2024) A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin. Diabetes therapy: research, treatment and education of diabetes and related disorders, 15(1), 215.

García-Campayo J, et al. (2024) Exploring the Relationship Between Self-Compassion and Compassion for Others: The Role of Psychological Distress and Wellbeing. Assessment, 31(5), 1038.

Vilsen SB, et al. (2024) Dataset of lithium-ion battery degradation based on a forklift mission profile for state-of-health estimation and lifetime prediction. Data in brief, 52, 109861.

Liang Z, et al. (2024) Discovering two general characteristic times of transient responses in solid oxide cells. Nature communications, 15(1), 4587.

Lin J, et al. (2024) Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023. Frontiers in pharmacology, 15, 1420478.

Gemler BT, et al. (2023) UltraSEQ, a Universal Bioinformatic Platform for Information-Based Clinical Metagenomics and Beyond. Microbiology spectrum, 11(3), e0416022.

Tovtik R, et al. (2023) Spin-Vibronic Control of Intersystem Crossing in Iodine-Substituted Heptamethine Cyanines. The Journal of organic chemistry, 88(11), 6716.